PSI is one of many organisations that are rooted within statistics and data analytics. As such, we believe that it is important for us to link with other appropriate organisations.
PSI is the association located in the UK for statisticians in the pharmaceutical industry, and therefore we have two representatives on the European Federation of Statisticians in the Pharmaceutical Industry council. EFSPI brings together representatives of statistical associations within Europe.
PSI has a joint award for Statistical Excellence within the Pharmaceutical Industry with the RSS. There are six-monthly meetings between representatives of both organisations to maintain good communication and identify opportunities to work together.
Recently PSI has linked with the Indian Association for Statistics in Clinical Trials (IASCT) and members of IASCT can join PSI at a reduced rate. PSI also welcomes members from any other countries, and from statisticians working in the wider clinical research and healthcare industries.
PSI has representatives on the Council of Biopharmaceutical Statisticians.
The Special Interest Groups include suitable representatives from, and interacts with, other organisations depending on the SIG topic. For instance, the Data Transparency SIG has had discussions with PhUSE members.
The PSI Careers and Academic Liaison Committee (CALC) promotes careers for statisticians and programmers within the pharmaceutical industry, and provides information and insights for those who might want to consider such a career through school and university activities, establishing links with relevant professional groups and via our Careers and Schools/Education websites.
The PSI Regulatory Committee is a joint PSI/EFSPI Committee which aims to provide an industry viewpoint on regulatory issues linked to statistics. This includes promoting best practice, reviewing and collating comments on regulatory policy and guidelines, driving debate on future guidance, and engaging with statisticians in European regulatory agencies, including the EMA Biostatistics Working Party (BSWP), as well as the statistical assessors at the Medicines & Healthcare products Regulatory Agency (MHRA).
PSI recognises that it is part of a wide community and therefore actively engages with the community.
An opportunity to meet statisticians from across the pharmaceutical industry in a relaxed and informal setting. An exciting program of events and a chance to work in small groups on a data analysis challenge. Lunch provided.
We are increasingly living in a data driven world. Data are collected in many different ways for a variety of purposes. As such, concerns around protecting the privacy of individuals have increased in recent times.
This hands-on course will provide a deep dive into 4 software packages used to design adaptive clinical trials. The course will start by providing a general overview of adaptive designs, explaining the different type of adaptations possible and the benefits of each design. Following this, participants will be given the opportunity to have a go at designing trials in R (using RPACTS), EAST, FACTS, and nQuery.
This practical training course will give a deep dive into performing Bayesian analyses in R and SAS. It is aimed at statisticians who need to be able to conduct Bayesian analyses as part of their day to day work. By the end of the course participants will be able to conduct their own analyses.
Our annual PSI Medical Statistics Careers Event, will be held at the De Montfort University in Leicester on Wednesday 4th March 2020.
This webinar will address operational issues of paramount importance within the healthcare industry with a view to using statistics for the benefit of patients. In attending this webinar, you'll hear more about work being conducted to address some operational issues we face in the health care industrys e.g. patient rectuitment, drug supply and meeting NHS 18 week targets.
PSI Toxicology SIG workshop – 16th and 17th March 2020 The Toxicology SIG provides a forum for statisticians working in regulatory/investigative toxicology, as well as most other pre-clinical areas, to discuss issues and interact with one another. This 1.5-day workshop will involve approximately 20 statisticians, focusing on discussions around “best practice” in the statistical analysis of various data types. The afternoon of Day 1 will include a 4.5 hour Bayesian training course focused towards applications in toxicology/pre-clinical, provided by Prof. Dr. Katja Ickstadt and is included in the workshop fee. The cost will be £270 including VAT per delegate, inclusive of food and one night’s accommodation (and the training course). The workshop is being held at the Crowne Plaza Hotel, Heathrow. The agenda and topics that will be discussed are yet to be finalised, but please get in touch with gareth.thomas@covance.com if you have suggestions. Full details will be circulated in the coming weeks.
This course is aimed at Statisticians and Programmers experienced in SAS, but little or no experience with R. An Introduction to R studio and the R language, statistical graphics, programming statistical models, simulations and more…
Designs of clinical trials with time to event primary endpoints usually rely on hazards being constant over time. A major challenge in immuno-oncology is the delayed onset of benefit with such therapies and the presence of non-proportional hazards. The impact of this needs to be accounted for in sample size calculations, analysis methodology and reporting. At this meeting, we will examine possible strategies to handle such features, which may not be fully known when the trial is initiated.
The ITIT course will take 25 delegates new to the industry on a complete drug development experience from discovery to marketing. They will visit 6 companies from October 2020 to July 2021 to learn about 6 topics from experts in their field. The ITIT course will have 6 sessions in continental Europe and 3 - 4 sessions in the UK. It promises to be a truly memorable course.
Would you like to be a part of a Statistical and Programming group, who have direct strategic impact on drug development, playing a key role in getting medicines to patients?
